TrialThe Lancet. Oncology2018

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Benjamin A Teply et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.